As of January 22, 2013, Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals.
Molecular Insight Pharmaceuticals, Inc. develops therapeutic radiopharmaceuticals and molecular imaging agents for use in oncology and cardiology. The company targets the development of a small-molecule chemistry platform to improve detection of primary and metastatic prostate cancer and to provide a systemic radiotherapy for relapsed and metastatic prostate cancer. Its products include technetium Tc 99m trofolastat, a clinical-stage molecular imaging agent for patients with metastatic prostate cancer; and 131I-MIP-1095, a prostate cancer therapy for systemic delivery of radiotherapy.
Company Details
- Employees
- 18
- Founded
- -
- Address
- 160 2nd St, Cambridge,massachusetts 02142,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- molecularinsight.com
- HQ
- Cambridge, Massachusetts
Molecular Insight Pharmaceuticals Questions
Molecular Insight Pharmaceuticals's website is molecularinsight.com
Molecular Insight Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/molecularinsight
Molecular Insight Pharmaceuticals has
18 employees.
View email and phone details for 18
employees at Molecular Insight Pharmaceuticals.
Molecular Insight Pharmaceuticals's industry is
Pharmaceutical Manufacturing
Molecular Insight Pharmaceuticals's top competitors are
Ikaika Therapeutics,
Ratio Therapeutics,
Retex Pharmaceuticals,
Panarum Corp,
Cloud Pharma,
Moleculeinsight,
Epivax Therapeutics, Inc.,
Izumi Biosciences,
Sgx Pharmaceuticals,
Molecular Cardiology Institute Inc.
Molecular Insight Pharmaceuticals's categories are Pharmaceutical Manufacturing
Molecular Insight Pharmaceuticals's founding year is 1997
